Literature DB >> 12441836

Thyroid and the eye.

Pamela Suzanne Chavis1.   

Abstract

Any thyroid cancer can metastasize to the uveal tract, even after decades; medullary thyroid cancer can be part of multiple endocrine neoplasia syndrome. Superior limbic keratoconjunctivitis and lagophthalmos are prognostic markers for more severe thyroid-associated ophthalmopathy (TAO). The restrictive ophthalmopathy of TAO may be associated with more sustained ocular hypertension and require topical therapy. Several new studies address the therapy of TAO, ranging from retrobulbar to oral to intravenous glucocorticoids, alone or combined with radiotherapy. Endonasal decompression of the posterior orbit can be done well for severe optic nerve compression; however, leaving the anterior orbital septum intact can minimize postoperative diplopia. Smoking increases the risk and relapse rate for ophthalmopathy. Thyrotropin receptor antigen on fibroblasts diffusely in the body is causative in TAO and pretibial myxedema with even increased urinary secretion of glycosaminoglycans. Corticosteroid-responsive patients show a sustained up-regulation of the Th1/Th2 profile.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441836     DOI: 10.1097/00055735-200212000-00002

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

Review 1.  An approach to the patient with painful ophthalmoplegia, with a focus on Tolosa-Hunt syndrome.

Authors:  Jonathan P Gladstone
Journal:  Curr Pain Headache Rep       Date:  2007-08

Review 2.  Painful ophthalmoplegia: overview with a focus on Tolosa-Hunt syndrome.

Authors:  Jonathan P Gladstone; David W Dodick
Journal:  Curr Pain Headache Rep       Date:  2004-08

3.  Confocal scan imaging and impression cytology of the cornea in a case of multiple endocrine neoplasia type-2b.

Authors:  Mohammad-Ali Javadi; Mozhgan Rezaei Kanavi; Amir Faramarzi; Sepehr Feizi; Fereidoun Azizi; Fatemeh Javadi
Journal:  J Ophthalmic Vis Res       Date:  2012-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.